NASDAQ:SNGX Soligenix (SNGX) Stock Price, News & Analysis $1.97 +0.08 (+4.44%) As of 05/7/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Soligenix Stock (NASDAQ:SNGX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Soligenix alerts:Sign Up Key Stats Today's Range$1.87▼$1.9850-Day Range$1.80▼$2.3952-Week Range$1.68▼$14.83Volume18,393 shsAverage Volume763,710 shsMarket Capitalization$4.93 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewSoligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.Read More… Soligenix Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks5th Percentile Overall ScoreSNGX MarketRank™: Soligenix scored higher than 5% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Soligenix. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Soligenix are expected to grow in the coming year, from ($4.65) to ($2.93) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Soligenix is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Soligenix is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSoligenix has a P/B Ratio of 0.51. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Soligenix's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.63% of the float of Soligenix has been sold short.Short Interest Ratio / Days to CoverSoligenix has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Soligenix has recently increased by 280.90%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSoligenix does not currently pay a dividend.Dividend GrowthSoligenix does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted5.63% of the float of Soligenix has been sold short.Short Interest Ratio / Days to CoverSoligenix has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Soligenix has recently increased by 280.90%, indicating that investor sentiment is decreasing significantly. News and Social Media0.4 / 5News Sentiment-1.30 News SentimentSoligenix has a news sentiment score of -1.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Soligenix this week, compared to 1 article on an average week.MarketBeat FollowsOnly 1 people have added Soligenix to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Soligenix insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.80% of the stock of Soligenix is held by insiders.Percentage Held by InstitutionsOnly 3.60% of the stock of Soligenix is held by institutions.Read more about Soligenix's insider trading history. Receive SNGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Soligenix and its competitors with MarketBeat's FREE daily newsletter. Email Address SNGX Stock News HeadlinesSoligenix (SNGX) to Release Quarterly Earnings on FridayMay 8 at 1:40 AM | americanbankingnews.comSoligenix (NASDAQ: SNGX) CEO Highlights Pipeline and Strategy in BioMedWire Podcast EpisodeMay 7 at 3:27 PM | theglobeandmail.comWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon bring Elon Musk's DOGE operation to its final, dramatic conclusion - with huge consequences for millions of investors. So if you have any money in the market... you're almost out of time to prepare. This plan has already been put in place... and can operate even if Elon's long gone from Washington. May 8, 2025 | Altimetry (Ad)Soligenix (NASDAQ: SNGX) CEO Highlights Pipeline and Strategy in BioMedWire Podcast EpisodeMay 7 at 3:27 PM | theglobeandmail.comIBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Christopher Schaber, CEO of Soligenix Inc.May 7 at 8:41 AM | finance.yahoo.comSoligenix $SNGX HyBryte™ Shows 75% Response Rate In Skin Cancer Trial, Backed By FDA FundingApril 30, 2025 | msn.comSolgenix shares rise on positive skin cancer treatment resultsApril 24, 2025 | investing.comFireside Chat with Christopher Schaber, Chief Executive Officer of Soligenix, Inc.April 24, 2025 | msn.comSee More Headlines SNGX Stock Analysis - Frequently Asked Questions How have SNGX shares performed this year? Soligenix's stock was trading at $2.69 on January 1st, 2025. Since then, SNGX stock has decreased by 27.0% and is now trading at $1.9650. View the best growth stocks for 2025 here. How were Soligenix's earnings last quarter? Soligenix, Inc. (NASDAQ:SNGX) posted its quarterly earnings data on Friday, March, 21st. The biopharmaceutical company reported ($1.14) earnings per share for the quarter, missing the consensus estimate of ($0.95) by $0.19. The biopharmaceutical company had revenue of $0.20 million for the quarter, compared to the consensus estimate of $0.20 million. Soligenix had a negative trailing twelve-month return on equity of 223.29% and a negative net margin of 1,473.38%. When did Soligenix's stock split? Soligenix's stock reverse split on Thursday, June 6th 2024. The 1-16 reverse split was announced on Thursday, June 6th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 6th 2024. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split. How do I buy shares of Soligenix? Shares of SNGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Soligenix own? Based on aggregate information from My MarketBeat watchlists, some other companies that Soligenix investors own include Tonix Pharmaceuticals (TNXP), Trevena (TRVN), Corbus Pharmaceuticals (CRBP), OPKO Health (OPK), T2 Biosystems (TTOO), iBio (IBIO) and Dynavax Technologies (DVAX). Company Calendar Last Earnings3/21/2025Today5/07/2025Next Earnings (Estimated)5/09/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SNGX CIK812796 Webwww.soligenix.com Phone(609) 538-8200Fax609-452-6467Employees20Year Founded1987Profitability EPS (Most Recent Fiscal Year)($6.11) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-6,140,000.00 Net Margins-1,473.38% Pretax Margin-2,220.75% Return on Equity-223.29% Return on Assets-74.18% Debt Debt-to-Equity RatioN/A Current Ratio2.28 Quick Ratio2.28 Sales & Book Value Annual Sales$840,000.00 Price / Sales5.87 Cash FlowN/A Price / Cash FlowN/A Book Value$3.83 per share Price / Book0.51Miscellaneous Outstanding Shares2,510,000Free Float2,440,000Market Cap$4.93 million OptionableNot Optionable Beta2.06 Social Links 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:SNGX) was last updated on 5/8/2025 by MarketBeat.com Staff From Our PartnersElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredAll Signs Point To Collapse - 401(k)s/IRAs /Are DoomedRetiring? Not so Fast..Hold Onto Your Bootstraps For A Long Road AheadAmerican Hartford Gold | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump to redistribute trillions of dollars Seeing how the media and other analysts are covering Trump’s actions – it’s laughable. At least it would be la...Porter & Company | SponsoredNew breed of trader (Wall Street hates us?)Wall Street big wigs and old-money bankers can’t touch this 1 type of stock. And that opens the door for tr...Timothy Sykes | Sponsored270x more lucrative than NVIDIA???270x more lucrative than NVIDIA??? If you've missed out on NVIDIA's recent 1,600% run... Don't worry. ...Behind the Markets | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Soligenix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Soligenix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.